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Abstract The aim of this non-randomized study was to
investigate whether there is any benefit in the extension of
antimicrobial treatment in patients with left-sided native
valve endocarditis in whom C-reactive protein levels are
still elevated after a standard course of therapy. There was
no statistically significant difference in outcome between
the group of patients in which treatment was extended in
comparison to the group in which treatment was ended at
the recommended time. It is unlikely that there is much to
gain from extending treatment based on elevated C-reactive
protein levels alone.
Introduction
Guidelines about the treatment of infective endocarditis (IE)
standardize the duration of antimicrobial therapy [1, 2].
Elevated C-reactive protein (CRP) values at the end of
therapy are regarded by some as a sign of active disease.
Therefore, antimicrobial therapy is sometimes prolonged
beyond the treatment period recommended in current
guidelines. The aim of this observational study was to
investigate whether patients with left-sided native valve
endocarditis in whom antimicrobial treatment is extended
because of elevated CRP levels have a better clinical
outcome than patients in whom antimicrobial treatment is
ended at the recommended time.
Methods
The study was designed as a multicenter cohort study in 23
hospitals in the Netherlands, of which eight are cardiotho-
racic surgery centres. The selection of hospitals was based
on an earlier nationwide epidemiologic study in the
Netherlands in which 70% of the cases of IE were admitted
to those centres [3]. The study was approved by the medical
ethical committees of all participating hospitals. From
November 2000 to October 2003, all adult patients
suspected of having left-sided native valve IE were reported
to the study centre. Patients with right-sided native valve
endocarditis, patients with prosthetic intracardiac material,
and patients who were already started on antimicrobial
therapy in the absence of CRP measurements were
excluded. Only cases which fulfilled the Duke criteria for
definite endocarditis were included in the analysis [4].
Written informed consent was obtained from all patients.
CRP measurements were performed at the start of antimi-
crobial treatment and each Monday, Wednesday, and Friday
thereafter until antibiotics were stopped. Standard duration
of antimicrobial treatment (SDoT) was defined according to
the American Heart Association guidelines [1]. Patients
with elevated CRP levels (>5 mg/L) at the end of a standard
course of therapy broke up into two groups based on the
local hospital policy which either advocated ending
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antimicrobial treatment in spite of CRP levels (Standard
Duration of Treatment group, SDoT group) or extending
antimicrobial treatment (Extended Duration of Treatment
group, EDoT group). Duration of treatment was calculated
from the first day that antimicrobial therapy was considered
to be adequate for the treatment of endocarditis until the
day that antibiotics were stopped. Duration of hospitaliza-
tion was calculated from the first day of effective
antimicrobial treatment until discharge. Osteomyelitis,
arthritis, visceral and cardiac abscesses, mycotic aneurysms,
and intracranial haemorrhages or infarcts were considered as
serious infectious complications. The following concomitant
diseases were recorded: diabetes mellitus with secondary
organ complications, end stage renal disease requiring
haemodialysis, cancer, auto-immune diseases requiring
immunosuppressive medication, and chronic obstructive
pulmonary disease with chronic bronchitis. Follow-up data
were collected by contacting the patient or his/her general
practitioner 12 weeks after the last day of antimicrobial
therapy. When the patient had been readmitted in this period,
data were collected from the hospital. Relapse of infection
was defined as infection with the same micro-organism
within 3 months.
Statistical analysis
We compared the clinical characteristics, infecting micro-
organisms, duration of antimicrobial treatment and hospi-
talization, serious infectious complications, and relapse and
mortality rates between the SDoT and the EDoT groups.
Chi-square test statistics were used for categorical variables
and Wilcoxon-Mann-Whitney test statistics for continuous
data. When the expected frequencies in a cell were less than
five, Fisher’s exact test was used.
Results
Two hundred fifty-one patients were reported to the study
centre. Reasons for exclusion were: prosthetic intracardiac
material (n=42), diagnosis rejected (n=28), treatment
before C-reactive protein measurements (n=27), right-sided
endocarditis (n=4), death before inclusion (n=3), and
age <18 years (n=2). Twenty-two patients refused to
participate. Of the 123 (49%) remaining patients, 35
underwent cardiac surgery, ten died, two were transferred
to non-participating hospitals, and in 15 patients CRP levels
normalized before the end of the standard therapy course.
Thus, 61 patients remained with an elevated CRP level at
the end of the standard duration of therapy. Twenty-one
(34%) of these patients were admitted into hospitals where
the duration of antimicrobial treatment did not depend on
CRP levels, and in these patients treatment was ended
(SDoT group). The 40 (66%) other patients were admitted
into hospitals where antimicrobial therapy was continued
beyond the standard duration if CRP values had not
normalized (EDoT group). Clinical characteristics, infecting
micro-organisms, and CRP levels of the patients in both
groups are summarized in Table 1. The distribution of
Table 1 Clinical characteristics, infecting micro-organisms and CRP values in 61 patients with elevated CRP levels at the end of the standard
course of antimicrobial therapy1
SDoT group2 n=21 EDoT group3 n=40 p value
Age, median (range) 65 (18–82) years 69 (25–82) years 0.32
Male : female 16:5 25:15 0.28
Micro-organism, distribution 0.04
Number (%)
Viridans streptococci 8 (38%) 20 (50%)
S. aureus 6 (29%) 2 (5%)
Str. bovis 2 (9.5%) 9 (23%)
Enterococci 2 (9.5%) 4 (10%)
HACEK4 0 (0%) 4 (10%)
CNS5 2 (9.5%) 1 (2.5%)
Other 1 (4.8%) 0 (0%)
Total 21 (100%) 40 (100%)
CRP6, median (range) 18 (6–171) mg/l 21 (6–94) mg/l 0.90
1 Standard duration of treatment (SDoT) as defined by the American Heart Association [1]
2 SDoT group: patients in whom treatment was ended after standard duration
3 SEoT group: patients in whom treatment was extended after standard duration
4 HACEK: Haemophilus spp., Actinobacillus actinomycetemcomitans, Cardiobacterium hominis, Eikenella spp. and Kingella kingae
5 CNS: coagulase negative staphylococci
6 C-reactive protein at the end of standard treatment duration in mg/l
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micro-organisms was significantly different between the
two groups (p=0.04). There was no significant difference in
mean CRP values at the end of the standard course of
therapy between the SDoT and the EDoT groups, which
were 38.1 mg/l and 29.6 mg/l, respectively.
At the end of the standard course of therapy, 11 patients
had had serious complications (Table 2). Cerebrovascular
accident was the most frequently observed complication.
The mean duration of antimicrobial treatment was 31 days
(range 14–42) in the SDoT group and 44 days (range 31–
104) days in the EDoT group (p<0.01). As would be
expected, the mean duration of hospitalization was also
significantly shorter in the SDoT group versus the EDoT
group: 43 days (range 15–129) versus 53 days (range 31–
122), respectively (p<0.05). There were no relapses of
infection in either group. The number of patients under-
going cardiac surgery after the standard course of antimi-
crobial therapy was 6 (29%) in the SDoT group and 17
(42%) in the EDoT group (p=0.29). There were no deaths
in the SDoT group versus two deaths in the EDoT group
(p=0.41). One patient died from cardiac failure caused by
heart valve regurgitation. There were no signs of infection
at the time of death. The other patient died from com-
plications of cardiac surgery while she was still on anti-
microbial therapy. Of the 61 patients, 24 (39%) had at least
one of the following concomitant diseases: autoimmune
diseases requiring immunosuppressive medication (n=9),
diabetes with secondary complications (n=8), cancer (n=6),
chronic obstructive pulmonary disease with chronic bron-
chitis (n=3), and end stage renal disease requiring
haemodialysis (n=3). Some patients had more than one
concomitant disease. There was no significant difference in
the number of patients with concomitant disease between
the SDoT group and the EDoT group (p=0.60).
Discussion
The aim of this study was to assess the effect of continuing
antimicrobial therapy in patients with left-sided native
valve endocarditis if CRP is still elevated at the end of
standard therapeutic courses. The results suggest that there
is no benefit in prolonging antimicrobial therapy in those
patients. There were no differences in outcome—as
measured by cardiac surgery, relapse rate, or mortality—
between patients in which treatment was ended (SDoT
group) and patients in which treatment was extended
(EDoT group). Several studies have been performed to
establish the diagnostic value of CRP measurement in
patients with IE [5–10]. In these studies, CRP is shown to
be elevated in almost every patient. Also, serial CRP
measurements during treatment have been studied as a
predictor of clinical outcome of endocarditis [11–14]. The
present study is the first to explore the role of CRP in
determining the duration of antimicrobial treatment. None
of the patients in the group in which treatment was ended,
in spite of elevated CRP levels (SDoT group), suffered a
relapse of infection or died. This was not a randomized
trial, so we cannot be completely sure that the differences
between the SDoT group and the EDoT group were
governed by chance only. However, the fact that the policy
of stopping or extending antimicrobial treatment beyond
the standard duration in the case of elevated CRP levels
was based on local hospital policy, and not on individual
patient characteristics, makes large differences unlikely.
The hospitals that followed the policy of prolonging
antimicrobial treatment included both cardiothoracic sur-
gery centres and centres that did not perform surgery.
Although the difference in the number of serious infectious
complications between the SDoT group (2 of 21 patients)
Table 2 Serious complications in patients with elevated CRP concentration at the end of the standard treatment
Infecting micro-organism Complication Days of antimicrobial treatment
SdoT group, n=21
Patient 1 S. aureus Psoas abscess 28
Patient 2 S. aureus CVA* 28
EdoT group, n=40
Patient 1 Viridans streptococci CVA 38
Patient 2 S. aureus CVA 45
Patient 3 Enterococ Osteomyelitis 42
Patient 4 Viridans streptococci Liver abscess 49
Patient 5 Viridans streptococci CVA, cardial abscess 104
Patient 6 Viridans streptococci CVA, cardial abscess 58
Patient 7 Kingella spp. CVA 31
Patient 8 S. aureus Arthritis 50
Patient 9 Viridans streptococci Osteomyelitis 32
*CVA cerebrovascular accident
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and the EDoT group (9 of 40 patients) was statistically not
significant, it was remarkable that there were more serious
infectious complications in the group in whom antimicro-
bial treatment was extended. The question remains why
CRP levels remain elevated in some patients. One expla-
nation may be the presence of concomitant disease which is
still present after the endocarditis has been cured. In our
population, 24 of the 61 patients (39%) had concomitant
disease. Another explanation for failure of CRP levels to
normalize after adequate antimicrobial treatment is the
existence of immunologic phenomena caused by endocar-
ditis as already mentioned in the first description of the
disease by William Osler [15]. These immunologic sequelae
can persist for some time after the micro-organisms that
caused the disease have been eradicated. A large and
randomized trial is required to provide a definite answer to
the question of whether there is any added benefit in
extending antimicrobial treatment in patients with elevated
CRP levels at the end of standard therapeutic courses. The
chance that such a trial will ever be performed is very small.
Because the incidence of endocarditis is low, it would require
a lengthy trial in a large number of hospitals. However, the
positive outcome in patients with elevated CRP levels in
which treatment was ended after a standard course makes it
unlikely that there is much to gain from extending treatment
based on elevated C-reactive protein alone.
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